Try Alerts Free   |   Login
Health Care › Electronic Computers

OMCL Price Correlated With Financials For Omnicell

Free historical financial statements for Omnicell Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 43 quarters since 2012. Compare with OMCL stock chart to see long term trends.

OMCL Stock Compared to Quarterly

OMCL Income Statement

Revenue, Net:348059000
Revenue Per Share:7.7953
Cost of Goods & Services Sold:188964000
Gross Profit:159095000
Selling, General & Admin Expense:115459000
Research & Development Expense:25171000
Total Operating Expenses:140630000
Operating Income:18465000
Income Taxes:543000
Net Income:16774000
Earnings Per Share, Basic:0.38
Shares Outstanding, Basic Avg:44649842

OMCL Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:21826000
Net Cash from Operations:21175000
Net Cash from Operations Per Share:0.4742
Repurchases/Buybacks Common Stock:0
Net Cash from Financing Activities:9056000
Property, Plant & Equipment Purchases:12762000
Purchases of Businesses, Net of Cash:0
Net Cash from Investing Activities:-15867000
Net Change in Cash & Equivalents:15062000

OMCL Balance Sheet

Cash and Cash Equivalents:283891000
Inventories:147096000
Total Current Assets:849132000
Property, Plant & Equipment, Net:88356000
Total Assets:2179685000
Accounts Payable:73517000
Total Short-Term Liabilities:376681000
Total Liabilities:1044290000

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
5,315,407 sh
-2,176,350 sh
-29%
$462,600
-$389,590
Vanguard Group Inc
4,282,955 sh
-515,107 sh
-11%
$372,745
-$173,034
Wellington Management Group Llp
2,312,980 sh
105,504 sh
5%
$201,298
-$49,802
Conestoga Capital Advisors, LLC
1,670,323 sh
-21,015 sh
-1%
$145,368
-$73,643
State Street Corp
1,497,197 sh
-13,346 sh
-1%
$130,301
-$41,523
Credit Suisse Ag/
1,282,164 sh
72,542 sh
6%
$111,587
-$26,008
Macquarie Group Ltd
1,207,569 sh
-10,710 sh
-1%
$105,138
-$33,441
Clearbridge Investments, LLC
1,172,229 sh
21,756 sh
2%
$102,019
-$28,847
Invesco Ltd.
1,123,086 sh
-258,405 sh
-19%
$97,742
-$59,403
Lazard Asset Management LLC
1,097,358 sh
212,817 sh
24%
$95,502
-$5,114
Geneva Capital Management LLC
964,465 sh
124,897 sh
15%
$83,937
-$11,563
Dimensional Fund Advisors LP
802,153 sh
-39,159 sh
-5%
$69,813
-$25,887
Geode Capital Management, LLC
801,005 sh
23,320 sh
3%
$69,711
-$18,750
Bank Of New York Mellon Corp
741,645 sh
76,628 sh
12%
$64,546
-$11,100
Arrowmark Colorado Holdings LLC
731,360 sh
171,220 sh
31%
$63,650
-$66
Champlain Investment Partners, LLC
725,390 sh
146,870 sh
25%
$63,131
-$2,676
American Century Companies Inc
691,627 sh
-157,069 sh
-19%
$60,192
-$36,347
Goldman Sachs Group Inc
654,625 sh
193,705 sh
42%
$56,972
$4,542
Bank Of America Corp /De/
603,689 sh
64,946 sh
12%
$52,539
-$8,743
Northern Trust Corp
600,727 sh
109,482 sh
22%
$52,281
-$11,329
COMPANY PROFILE
Organization and Summary of Significant Accounting Policies Business

Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” collectively refer to Omnicell, Inc. and its subsidiaries.

Basis of Presentation

The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

On September 9, 2021, the Company completed its acquisition of RxInnovation Inc., operating as FDS Amplicare (“FDS Amplicare”); on December 29, 2021, the Company completed its acquisition of ReCept Holdings, Inc. (“ReCept”); and on December 31, 2021, the Company completed its acquisition of MarkeTouch Media, LLC (“MarkeTouch Media”). The Consolidated Financial Statements include the results of operations of these recently acquired companies, commencing as of the respective acquisition dates. The significant accounting policies of the acquired businesses have been aligned to conform to the accounting policies of Omnicell.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. Those policies are revenue recognition; allowance for credit losses for accounts receivable and unbilled receivables; notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; capitalized software development costs; impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combinations; convertible senior notes; share-based compensation; and accounting for income taxes. As of December 31, 2021, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.

Segment Reporting

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

Foreign Currency Translation and Remeasurement

Most of the Company’s foreign subsidiaries use the local currency of their respective countries as their functional curren

Data imported from Omnicell Inc SEC filings. Check original filings before making any investment decision.